- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.
EP: 1.Overview and Prevalence of Biologics
EP: 2.Defining Unbranded Biologics
EP: 3.Clinical Impacts of Biologics on Patient Quality of Care
EP: 4.Pipeline Development and Future Implications of Unbranded Biologics
EP: 5.Emphasizing Biologics Space as Payer Priority
EP: 6.Evolving Complexity of Biologics Space
EP: 7.Differentiating Between Unbranded Biologics and Biosimilars
EP: 8.The Impact of Unbranded Biologics in the Evolving Treatment Landscape of Autoimmune Disease
EP: 9.Implications of Multiple Switching with Biologic Therapies
EP: 10.Factors Affecting Biologics Affordability for Patient Treatment
EP: 11.Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
Kareem Karara, PharmD, BCPS, CCHP: As far as unbranded biologics that may be targeted for pipeline development in the near future, I’d love to see expanded options in the autoimmune and oncology disease spaces. These are 2 areas that are commonly managed with a range of biologic therapies and biosimilars, and they continue to be areas where we see growth of biologic management in terms of how we manage these diseases.
Regarding the future implications of unbranded biologics and biosimilars, I’m excited to see what’s to come. It’s important to see increased competition in the market for biologic drugs, which ultimately will improve patient access to these clinically important therapies and the role they have in managing chronic disease.
Transcript edited for clarity.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
